What is Aphinity trial?
The APHINITY trial was a Phase III, large, prospective, randomized, multicenter, double-blind, placebo-controlled trial of patients with HER2+ early breast cancer (EBC).
What percentage of breast cancer is triple positive?
Prevalence. Overall, roughly 10 percent of tumors might be considered triple-positive, though large-scale studies looking at the epidemiology are lacking. In addition, the degree of estrogen positivity can vary between these tumors.
What is invasive disease free survival?
Invasive disease-free survival (IDFS), defined as occurrence of any of the following: ipsilateral invasive breast cancer recurrence, regional invasive breast cancer recurrence, distant recurrence, death attributable to any cause, contralateral invasive breast cancer, or second non-breast invasive cancer.
Is pertuzumab an anthracycline?
Pertuzumab, trastuzumab, and two commonly used anthracycline-based regimens for the neoadjuvant treatment of early breast cancer were associated with cardiac/general safety profiles and pathologic complete response rates consistent with prior pertuzumab studies.
When is the third interim analysis of aphinity?
The APHINITY study continues as planned with the third interim analysis of OS scheduled for 2022. Continued follow-up of these patients is very important to determine a possible OS benefit. 1 No new cardiac safety concerns emerged.
What are the primary endpoints of the aphinity study?
The primary efficacy endpoint of the APHINITY study is iDFS, which in this study is defined as the time a patient lives without return of invasive breast cancer at any site, or death from any cause after adjuvant treatment. Secondary endpoints include cardiac and overall safety, OS, disease-free survival and health-related quality of life.
How is eligibility for Roche HER2 targeted Medicine determined?
Eligibility for treatment with Roche’s HER2-targeted medicines is determined via a diagnostic test which identifies people who will likely benefit from these medicines at the onset of their disease. Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
What kind of breast cancer does Roche treat?
HER2-positive breast cancer is a particularly aggressive form of the disease that affects approximately 15-20% of patients. 11 Roche has developed three innovative medicines that have helped transform the treatment of HER2-positive breast cancer: Herceptin ® (trastuzumab), Perjeta ® (pertuzumab) and Kadcyla ® (trastuzumab emtansine).